SecBot SecBot
Institutional Cluster

ARWR

ARROWHEAD PHARMACEUTICALS, INC.
MIXED
Impact 5/10
Horizonweeks Processed2mo ago
Institutional cluster: 42 buyers, 43 sellers (mixed)
Actionable Insight ◆ Mixed

The Norges Bank entry is a strong vote of confidence, but the broad-based trimming by quant funds and mega-passive managers, combined with zero insider buying, creates a mixed signal. Monitor for any catalyst (pipeline data, partnership news) that could explain the sovereign wealth fund's conviction. The 45-day 13F reporting lag means these positions may already be adjusted, watch for subsequent filings and price action for confirmation.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$82.76
T+0 close · Sep 10, 2026 · via day close
Latest settled
−26.61%
T+20 · $60.74 · next T+60 in 17d
Vs SPY
−28.73%
α at T+20
Latest observation
−40.04%
T+45 · FF3 residual α
  1. T+0 · Sep 10 $82.76entry
  2. T+1 · 2mo ago +0.11%α −0.74% · $82.85
  3. T+5 · 2mo ago −18.15%α −17.65% · $67.74
  4. T+20 · 6w ago −26.61%α −28.73% · $60.74
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ARWR saw a mixed institutional cluster in Q2 2026 with 42 buyers accumulating $452.7M and 43 sellers reducing by $147.6M. The most notable event was Norges Bank taking a massive new $317.6M position, while several quant and mega-passive funds (D.E. Shaw, RenTech, Goldman Sachs, UBS) trimmed significantly. The net buying of $305.1M is dominated by the sovereign wealth fund's entry, but the broad-based selling by 43 institutions and zero insider buying (confluence score 25/100, divergent) tempers conviction. The amplifier verdict for inst-earnings + inst-offering context supports moderate impact, but the lack of insider corroboration and mixed direction warrants a neutral-to-mildly-bullish stance.

Key Financial Metrics

Direction
mixed
Buy Value
$522.6M
Sell Value
$147.6M
Net Flow
$305.0M

Institutional Positions

Net institutional flow: $305.0M

▲ Buyers (42)

InstitutionActionChangePosition ValueValue Δ
Norges BankNEWNot reported$317.6M$317.6M
Dimensional Fund AdvisorsADD+94.2%$96.3M$58.2M
MillenniumNEWNot reported$26.8M$26.8M
Susquehanna International GroupADD+57.5%$48.6M$24.9M
Jane Street GroupDOUBLED+1143.8%$16.0M$15.0M

▼ Sellers (43)

InstitutionActionChangePrev ValueValue Δ
D.E. ShawTRIM-63.5%$74.2M-$39.1M
Pictet Asset Management HoldingTRIM-55%$79.6M-$32.9M
RenTechTRIM-54.8%$65.0M-$26.8M
Goldman SachsTRIM-33.9%$109.1M-$15.4M
UBSTRIM-35.5%$83.8M-$13.6M

Key Facts

  • 42 institutional buyers added $452.7M in new ARWR positions in Q2 2026
  • 43 institutional sellers reduced holdings by $147.6M
  • Norges Bank initiated a new $317.6M position (3.90M shares), the largest single move
  • D.E. Shaw trimmed 63.5% (-$39.1M), RenTech trimmed 54.8% (-$26.8M)
  • Goldman Sachs, UBS, and Northern Trust each trimmed 28-36% of their positions
  • Zero open-market insider buying during the quarter (confluence score 25/100, divergent)
  • Net institutional inflow of ~$305M, but broad-based selling by 43 funds creates mixed signal

Financial Impact

Net institutional inflow of approximately $305M (42 buyers adding $452.7M vs 43 sellers reducing $147.6M), dominated by Norges Bank's $317.6M new position

institutional ownershipfloatnet institutional flow

Risk Factors

  • 13F data is 45+ days stale; positions may have been unwound since quarter-end
  • Broad selling by 43 institutions suggests lack of broad conviction despite Norges Bank's large entry
  • Zero insider buying and divergent confluence score (25/100) weakens the bullish signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ARWR-2026-Q2

Track record

7 reports on ARWR

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.69% at T+5 after the Nov 2, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $47.78 to $44.21 ▲ +7.47% +5.56% vs SPY
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $57.46 to $58.16 ▲ +1.22% +0.91% vs SPY
  3. Nov 4, 202612d ago 8-K Bullish 5/10 Entry $61.65 to $57.46 ▼ −6.80% −2.39% vs SPY
  4. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $59.53 to $61.65 ▼ −3.56% −1.91% vs SPY
  5. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Viewing Entry $82.76 to $82.85 ▲ +0.11% −0.74% vs SPY
  6. Aug 20, 202612w ago Insider Cluster Neutral 2/10 Entry $87.11 to $86.73 ▼ −0.44% −0.14% vs SPY
  7. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $81.04 to $81.82 ▲ +0.96% +0.18% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (11h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026